CDC Recommends ZOSTAVAX(R), Merck's (MRK) Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
More News related to MRK
- BeaconEquity.com Issues Technical Trade Alerts on Healthcare Stocks: ZILA, VITA, EYE, JNJ, NVS, MRK
- Analyst Reports for Bristol-Myers Squibb Company, Merck & Co. Inc., Idearc Inc., and Northwest Airlines Corporation
- Tekmira Pharmaceuticals Publishes Research That Addresses Critical Issue in the RNAi Field
- FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
- The Merck Index Women in Chemistry Scholarships to be Presented at American Chemical Society National Meeting
The U.S. Centers for Disease Control and Prevention (CDC) has adopted the unanimous recommendation of its Advisory Committee on Immunization Practices (ACIP) for the use of Merck's (NYSE: MRK) ZOSTAVAX(R) (Zoster Vaccine Live) for the prevention of shingles in adults aged 60 and older. ZOSTAVAX is the only vaccine to prevent shingles, a frequently painful disease marked by a blistering rash that is caused by the reactivation of the chickenpox virus. These final vaccination guidelines were published online today in the CDC's Morbidity and Mortality Weekly Report (MMWR) and are now available to health care providers.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.13Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
shingles
Jack Grainger on May 15, 2008 02:10 PMHow about some pictures of shingles,